-
1
-
-
84555190775
-
Insights into antibiotic resistance through metagenomic approaches
-
Schmieder R, Edwards R. 2012. Insights into antibiotic resistance through metagenomic approaches. Future Microbiol. 7:73-89. http://dx.doi.org/10.2217/fmb.11.135.
-
(2012)
Future Microbiol
, Issue.7
, pp. 73-89
-
-
Schmieder, R.1
Edwards, R.2
-
2
-
-
77957980707
-
Origins and evolution of antibiotic resistance
-
Davies J, Davies D. 2010. Origins and evolution of antibiotic resistance. Microbiol. Mol. Biol. Rev. 74:417-433. http://dx.doi.org/10.1128/MMBR .00016-10.
-
(2010)
Microbiol. Mol. Biol. Rev
, Issue.74
, pp. 417-433
-
-
Davies, J.1
Davies, D.2
-
3
-
-
79953710021
-
Novel classes of antibiotics or more of the same?
-
Coates ARM, Halls G, Hu Y. 2011. Novel classes of antibiotics or more of the same? Br. J. Pharmacol. 163:184-194. http://dx.doi.org/10.1111/j .1476-5381.2011.01250.x.
-
(2011)
Br. J. Pharmacol
, Issue.163
, pp. 184-194
-
-
Arm, C.1
Halls, G.2
Hu, Y.3
-
4
-
-
84879021964
-
-
Anonymous. Pfizer, Inc., New York, NY
-
Anonymous. 2012. Zyvox package insert. Pfizer, Inc., New York, NY.
-
(2012)
Zyvox Package Insert
-
-
-
5
-
-
84873642637
-
Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: The ESTABLISH-1 randomized trial
-
Prokocimer P, De Anda C, Fang E, Mehra P, Das A. 2013. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA 309:559-569. http://dx.doi.org/10.1001/jama.2013.241.
-
(2013)
JAMA
, vol.309
, pp. 559-569
-
-
Prokocimer, P.1
De Anda, C.2
Fang, E.3
Mehra, P.4
Das, A.5
-
6
-
-
84871233763
-
The emerging problem of linezolid-resistant Staphylococcus
-
Gu B, Kelesidis T, Tsiodras S, Hindler J, Humphries RM. 2013. The emerging problem of linezolid-resistant Staphylococcus. J. Antimicrob. Chemother. 68:4-11. http://dx.doi.org/10.1093/jac/dks354.
-
(2013)
J. Antimicrob. Chemother
, Issue.68
, pp. 4-11
-
-
Gu, B.1
Kelesidis, T.2
Tsiodras, S.3
Hindler, J.4
Humphries, R.M.5
-
8
-
-
84870158882
-
Potent activity of GSK1322322, a novel peptide deformylase inhibitor, in a Haemophilus influenzae and Streptococcus pneumoniae respiratory tract infection model, abstr. F1-2115
-
Boston, MA, 12 to 15 September 2010
-
Lewandowski T, Peters T, Simon N, Kulkarni S. 2010. Potent activity of GSK1322322, a novel peptide deformylase inhibitor, in a Haemophilus influenzae and Streptococcus pneumoniae respiratory tract infection model, abstr. F1-2115. Proceedings of the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, 12 to 15 September 2010.
-
(2010)
Proceedings of the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
-
-
Lewandowski, T.1
Peters, T.2
Simon, N.3
Kulkarni, S.4
-
9
-
-
80355137256
-
Determination of disk diffusion and MIC quality control ranges for GSK1322322, a novel peptide deformylase inhibitor
-
Ross JE, Scangarella-Oman NE, Miller LA, Sader HS, Jones RN. 2011. Determination of disk diffusion and MIC quality control ranges for GSK1322322, a novel peptide deformylase inhibitor. J. Clin. Microbiol. 49:3928-3930. http://dx.doi.org/10.1128/JCM.01213-11.
-
(2011)
J. Clin. Microbiol
, Issue.49
, pp. 3928-3930
-
-
Ross, J.E.1
Scangarella-Oman, N.E.2
Miller, L.A.3
Sader, H.S.4
Jones, R.N.5
-
10
-
-
84876204256
-
Comparative analysis of the antibacterial activity of a novel peptide deformylase inhibitor, GSK1322322
-
O'Dwyer K, Hackel M, Hightower S, Hoban D, Bouchillon S, Qin D, Aubart K, Zalacain M, Butler D. 2013. Comparative analysis of the antibacterial activity of a novel peptide deformylase inhibitor, GSK1322322. Antimicrob. Agents Chemother. 57:2333-2342. http://dx.doi.org/10.1128/AAC.02566-12.
-
(2013)
Antimicrob. Agents Chemother
, Issue.57
, pp. 2333-2342
-
-
O'Dwyer, K.1
Hackel, M.2
Hightower, S.3
Hoban, D.4
Bouchillon, S.5
Qin, D.6
Aubart, K.7
Zalacain, M.8
Butler, D.9
-
11
-
-
84870158882
-
Potent activity of GSK1322322, a novel peptide deformylase inhibitor, after oral dosing in a murine multi-drug resistant Staphylococcus aureus infection model, abstr. F1-2113
-
Boston, MA, 12 to 15 September 2010
-
Lewandowski T, DeMarsh P, Peters T, Kulkarni S. 2010. Potent activity of GSK1322322, a novel peptide deformylase inhibitor, after oral dosing in a murine multi-drug resistant Staphylococcus aureus infection model, abstr. F1-2113. Proceedings of the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, 12 to 15 September 2010.
-
(2010)
Proceedings of the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
-
-
Lewandowski, T.1
Demarsh, P.2
Peters, T.3
Kulkarni, S.4
-
12
-
-
84876223355
-
Single-dose safety, tolerability, and pharmacokinetics of the antibiotic GSK1322322, a novel peptide deformylase inhibitor
-
Naderer OJ, Dumont E, Zhu J, Kurtinecz M, Jones LS. 2013. Single-dose safety, tolerability, and pharmacokinetics of the antibiotic GSK1322322, a novel peptide deformylase inhibitor. Antimicrob. Agents Chemother. 57: 2005-2009. http://dx.doi.org/10.1128/AAC.01779-12.
-
(2013)
Antimicrob. Agents Chemother
, vol.57
, pp. 2005-2009
-
-
Naderer, O.J.1
Dumont, E.2
Zhu, J.3
Kurtinecz, M.4
Jones, L.S.5
-
13
-
-
84877859809
-
Effect of H2 blockade and food on single-dose pharmacokinetics of GSK1322322, a peptide deformylase inhibitor antibacterial
-
Naderer OJ, Dumont E, Zhu J, Kurtinecz M, Jones LS. 2013. Effect of H2 blockade and food on single-dose pharmacokinetics of GSK1322322, a peptide deformylase inhibitor antibacterial. Antimicrob. Agents Chemother. 57:2556-2561. http://dx.doi.org/10.1128/AAC.02505-12.
-
(2013)
Antimicrob. Agents Chemother
, Issue.57
, pp. 2556-2561
-
-
Naderer, O.J.1
Dumont, E.2
Zhu, J.3
Kurtinecz, M.4
Jones, L.S.5
-
14
-
-
84880750563
-
Safety, tolerability and pharmacokinetics of repeat dosing of the antibiotic GSK1322322, a peptide deformylase inhibitor: A randomized placebocontrolled study
-
Naderer OJ, Dumont E, Zhu J, Kurtinecz M, Jones LS. 2013. Safety, tolerability and pharmacokinetics of repeat dosing of the antibiotic GSK1322322, a peptide deformylase inhibitor: a randomized placebocontrolled study. J. Antimicrob. Chemother. 68:1901-1909. http://dx.doi.org/10.1093/jac/dkt097.
-
(2013)
J. Antimicrob. Chemother
, vol.68
, pp. 1901-1909
-
-
Naderer, O.J.1
Dumont, E.2
Zhu, J.3
Kurtinecz, M.4
Jones, L.S.5
-
15
-
-
84891505001
-
Safety, tolerability, and pharmacokinetics of oral and intravenous administration of GSK1322322, a peptide deformylase inhibitor
-
Naderer OJ, Jones LS, Zhu J, Kurtinecz M, Dumont E. 2013. Safety, tolerability, and pharmacokinetics of oral and intravenous administration of GSK1322322, a peptide deformylase inhibitor. J. Clin. Pharmacol. 53: 1168-1176. http://dx.doi.org/10.1002/jcph.150.
-
(2013)
J. Clin. Pharmacol
, Issue.53
, pp. 1168-1176
-
-
Naderer, O.J.1
Jones, L.S.2
Zhu, J.3
Kurtinecz, M.4
Dumont, E.5
-
16
-
-
84866648642
-
Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: Update from the Biomarkers Consortium of the Foundation for the National Institutes of Health
-
Talbot GH, Powers JH, Fleming TR, Siuciak JA, Bradley J, Boucher H, CABP-ABSSSI Project Team. 2012. Progress on developing endpoints for registrational clinical trials of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections: update from the Biomarkers Consortium of the Foundation for the National Institutes of Health. Clin. Infect. Dis. 55:1114-1121. http://dx.doi.org/10.1093/cid/cis566.
-
(2012)
Clin. Infect. Dis
, Issue.55
, pp. 1114-1121
-
-
Talbot, G.H.1
Powers, J.H.2
Fleming, T.R.3
Siuciak, J.A.4
Bradley, J.5
Boucher, H.6
Project Team, C.7
-
18
-
-
6444222075
-
Detection of Panton-Valentine leukocidin gene in Staphylococcus aureus by LightCycler PCR: Clinical and epidemiological aspects
-
Johnsson D, Mölling P, Stralin K, Söderquist B. 2004. Detection of Panton-Valentine leukocidin gene in Staphylococcus aureus by LightCycler PCR: clinical and epidemiological aspects. Clin. Microbiol. Infect. 10: 884-889. http://dx.doi.org/10.1111/j.1469-0691.2004.00976.x.
-
(2004)
Clin. Microbiol. Infect
, vol.10
, pp. 884-889
-
-
Johnsson, D.1
Mölling, P.2
Stralin, K.3
Söderquist, B.4
-
19
-
-
0033496604
-
Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia
-
Lina G, Piémont Y, Godail-Gamot F, Bes M, Peter M-O, Gauduchon V, Vandenesch F, Etienne J. 1999. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin. Infect. Dis. 29:1128-1132. http://dx.doi.org/10.1086/313461.
-
(1999)
Clin. Infect. Dis
, vol.29
, pp. 1128-1132
-
-
Lina, G.1
Piémont, Y.2
Godail-Gamot, F.3
Bes, M.4
Peter, M.-O.5
Gauduchon, V.6
Vandenesch, F.7
Etienne, J.8
-
20
-
-
0242677610
-
Pulsed-field gel electrophoresis typing of oxacillinresistant Staphylococcus aureus isolates from the United States: Establishing a national database
-
McDougal LK, Steward CD, Killgore GE, Chaitram JM, McAllister SK, Tenover FC. 2003. Pulsed-field gel electrophoresis typing of oxacillinresistant Staphylococcus aureus isolates from the United States: establishing a national database. J. Clin. Microbiol. 41:5113-5120. http://dx.doi.org/10.1128/JCM.41.11.5113-5120.2003.
-
(2003)
J. Clin. Microbiol
, vol.41
, pp. 5113-5120
-
-
McDougal, L.K.1
Steward, C.D.2
Killgore, G.E.3
Chaitram, J.M.4
McAllister, S.K.5
Tenover, F.C.6
-
21
-
-
34447272463
-
Allelic variation in genes encoding Panton-Valentine leukocidin from community-associated Staphylococcus aureus
-
Wolter DJ, Tenover FC, Goering RV. 2007. Allelic variation in genes encoding Panton-Valentine leukocidin from community-associated Staphylococcus aureus. Clin. Microbiol. Infect. 13:827-830. http://dx.doi.org/10.1111/j.1469-0691.2007.01763.x.
-
(2007)
Clin. Microbiol. Infect
, vol.13
, pp. 827-830
-
-
Wolter, D.J.1
Tenover, F.C.2
Goering, R.V.3
-
23
-
-
63649121640
-
Development and initial validation of an expanded and revised version of the short-form McGill pain questionnaire (SF-MPQ-2
-
Dworkin RH, Turk DC, Revicki DA, Harding G, Coyne KS, Peirce-Sandner S, Bhagwat D, Everton D, Burke LB, Cowan P, Farrar JT, Hertz S, Max MB, Rappaport BA, Melzack R. 2009. Development and initial validation of an expanded and revised version of the short-form McGill pain questionnaire (SF-MPQ-2). Pain 144:35-42. http://dx.doi.org/10.1016/j.pain.2009.02.007.
-
(2009)
Pain
, vol.144
, pp. 35-42
-
-
Dworkin, R.H.1
Turk, D.C.2
Revicki, D.A.3
Harding, G.4
Coyne, K.S.5
Peirce-Sandner, S.6
Bhagwat, D.7
Everton, D.8
Burke, L.B.9
Cowan, P.10
Farrar, J.T.11
Hertz, S.12
Max, M.B.13
Rappaport, B.A.14
Melzack, R.15
-
24
-
-
84904718296
-
Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): A randomised, double-blind, phase 3, non-inferiority trial
-
Moran GJ, Fang E, Corey GR, Das AF, De Anda C, Prokocimer P. 2014. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect. Dis. 14:696-705. http://dx.doi.org/10.1016/S1473-3099(14)70737-6.
-
(2014)
Lancet Infect. Dis
, vol.14
, pp. 696-705
-
-
Moran, G.J.1
Fang, E.2
Corey, G.R.3
Das, A.F.4
De Anda, C.5
Prokocimer, P.6
-
25
-
-
81555200433
-
Randomized, double-blind, phase II, multicenter study evaluating the safety/tolerability and efficacy of JNJ-Q2, a novel fluoroquinolone, compared with linezolid for treatment of acute bacterial skin and skin structure infection
-
Covington P, Davenport JM, Andrae D, O'Riordan W, Liverman L, McIntyre G, Almenoff J. 2011. Randomized, double-blind, phase II, multicenter study evaluating the safety/tolerability and efficacy of JNJ-Q2, a novel fluoroquinolone, compared with linezolid for treatment of acute bacterial skin and skin structure infection. Antimicrob. Agents Chemother. 55:5790-5797. http://dx.doi.org/10.1128/AAC.05044-11.
-
(2011)
Antimicrob. Agents Chemother
, Issue.55
, pp. 5790-5797
-
-
Covington, P.1
Davenport, J.M.2
Andrae, D.3
O'Riordan, W.4
Liverman, L.5
McIntyre, G.6
Almenoff, J.7
-
26
-
-
84908587678
-
Pharmacokinetics/pharmacodynamics (PK/PD) of peptide deformylase inhibitor GSK1322322 against Staphylococcus aureus in a rat abscess model, abstr. P920
-
Berlin, Germany, 27 to 30 April 2013
-
Lewandowski T, Hoover J, Rittenhouse S. 2013 Pharmacokinetics/pharmacodynamics (PK/PD) of peptide deformylase inhibitor GSK1322322 against Staphylococcus aureus in a rat abscess model, abstr. P920. 23rd European Congress of Clinical Microbiology and Infectious Diseases, Berlin, Germany, 27 to 30 April 2013.
-
(2013)
23rd European Congress of Clinical Microbiology and Infectious Diseases
-
-
Lewandowski, T.1
Hoover, J.2
Rittenhouse, S.3
|